Dr. Michal Sheleg on a Novel Immunotherapy Platform for Solid Tumor Treatment
By Michal Sheleg, PhD, Rob Dillard - Last Updated: June 20, 2024Recently, Pluri Inc. launched its placental allogeneic MAIT cell platform for immunotherapy treatment of solid tumors, a significant medical need that currently lacks effective treatments. Pluri’s MAIT cells are isolated from the human placenta, a source rich in highly potent allogeneic immune cells, and they offer substantial potential benefits compared with conventional T cells.
Advertisement
DocWire News spoke with Michal Sheleg, PhD, medical director at Pluri, to learn more about the impact this platform could have on the fight against cancer.
Advertisement
Related Posts
Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.
Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.
AI analysis provides an opportunity for timely intervention to improve the ability to swallow as well as quality of life.
Euphorbis tirucalli leaf extract has the potential ability to inhibit EBV-positive cell proliferation.
A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as MARCO.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.